Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Overall, women with MS have a 26% increased risk of mental illness during pregnancy and a 33% increased risk after giving birth, compared to women without the degenerative nerve disease.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...

This article explores insights from Richmond-area therapists on Ketamine-Assisted Psychotherapy (KAP) and EMDR therapy, focusing on their applications in treating trauma, CPTSD, and mental health ...